C. Arriens, A. Askanase, R. Furie, Eric F Morand, Ronald Van Vollenhoven, Kevin Connors, M. Davey, N. Delev, V. Shah, A. Stevens, Thomas L. Wegman, C. Hobar
{"title":"LP-179:针对活动性系统性红斑狼疮患者口服选择性变构酪氨酸激酶2 (TYK2)抑制剂deucravacitinib的2项3期、双盲、安慰剂对照全球试验设计","authors":"C. Arriens, A. Askanase, R. Furie, Eric F Morand, Ronald Van Vollenhoven, Kevin Connors, M. Davey, N. Delev, V. Shah, A. Stevens, Thomas L. Wegman, C. Hobar","doi":"10.1136/lupus-2023-kcr.254","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":359413,"journal":{"name":"E-Poster Presentation","volume":"258 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus\",\"authors\":\"C. Arriens, A. Askanase, R. Furie, Eric F Morand, Ronald Van Vollenhoven, Kevin Connors, M. Davey, N. Delev, V. Shah, A. Stevens, Thomas L. Wegman, C. Hobar\",\"doi\":\"10.1136/lupus-2023-kcr.254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":359413,\"journal\":{\"name\":\"E-Poster Presentation\",\"volume\":\"258 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"E-Poster Presentation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/lupus-2023-kcr.254\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"E-Poster Presentation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2023-kcr.254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus